Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2002.02.082 on June 17 2002

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eder, J. P.
Right arrow Articles by Kufe, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eder, J. P., Jr
Right arrow Articles by Kufe, D. W.
Journal of Clinical Oncology, Vol 20, Issue 18 (September), 2002: 3772-3784
© 2002 American Society for Clinical Oncology

Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily

By Joseph P. Eder, Jr, Jeffrey G. Supko, Jeffrey W. Clark, Thomas A. Puchalski, Rocio Garcia-Carbonero, David P. Ryan, Lawrence N. Shulman, Joann Proper, Moira Kirvan, Barbara Rattner, Susan Connors, Mary T. Keogan, Milos J. Janicek, William E. Fogler, Lowell Schnipper, Nancy Kinchla, Carolyn Sidor, Eric Phillips, Judah Folkman, Donald W. Kufe

From the Division of Adult Oncology, Dana-Farber Cancer Institute; Divisions of Hematology/Oncology, Departments of Medicine, Brigham and Women’s Hospital, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center; Department of Surgery, Children’s Hospital; and Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA; and EntreMed, Rockville, MD.

Address reprint requests to J.P. Eder, Jr, MD, Dana-Farber Cancer Institute, 44 Binney St, Rm M1B34, Boston, MA 02115; email: jeder{at}partners.org

PURPOSE: To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in adult patients with refractory solid tumors.

PATIENTS AND METHODS: The daily dose was increased from 15 to 240 mg/m2 by a factor of 100% in cohorts of three patients. In the absence of dose-limiting toxicity, uninterrupted treatment was continued until the tumor burden increased by more than 50% from baseline. Correlative studies included dynamic contrast-enhanced magnetic resonance imaging of tumor blood flow, urinary vascular endothelial growth factor and basic fibroblast growth factor levels, rhEndostatin serum pharmacokinetics, and monitoring of circulating antibodies to rhEndostatin.

RESULTS: There were no notable treatment related toxicities among 15 patients receiving a total of 50 monthly cycles of rhEndostatin. One patient with a pancreatic neuroendocrine tumor had a minor response and two patients showed disease stabilization. Linearity in the pharmacokinetics of rhEndostatin was indicated by dose-proportionate increases in the area under the curve for the first dose and the peak serum concentration at steady state. Daily systemic exposure to rhEndostatin in patients receiving 240 mg/m2/d was approximately 50% lower than that provided by the therapeutically optimal dose in preclinical studies.

CONCLUSION: rhEndostatin administered as a 20-minute daily IV injection at doses up to 240 mg/m2 showed no significant toxicities. Evidence of clinical benefit was observed in three patients. Due to high variability between the peak and trough serum concentrations associated with the repeated short IV infusion schedule, daily serum drug levels only briefly exceeded concentrations necessary for in vitro antiangiogenic effects.

Preliminary results of the study were presented at the eleventh National Cancer Institute/European Organization for Research and Treatment of Cancer/American Association of Cancer Research symposium on new drugs in cancer therapy, Amsterdam, the Netherlands, November 7-10, 2000, and the Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

The first two authors contributed equally to this study.

This article was published ahead of print at www.jco.org.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
B. H.L. Goulart, J. W. Clark, H. H. Pien, T. G. Roberts, S. N. Finkelstein, and B. A. Chabner
Trends in the Use and Role of Biomarkers in Phase I Oncology Trials
Clin. Cancer Res., November 15, 2007; 13(22): 6719 - 6726.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Shi, Y. Huang, H. Zhou, X. Song, S. Yuan, Y. Fu, and Y. Luo
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Blood, October 15, 2007; 110(8): 2899 - 2906.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
J. Dent. Res., October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Isayeva, D. Chanda, L. Kallman, I.-E. A. Eltoum, and S. Ponnazhagan
Effects of Sustained Antiangiogenic Therapy in Multistage Prostate Cancer in TRAMP Model
Cancer Res., June 15, 2007; 67(12): 5789 - 5797.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Jackson, J. P.B. O'Connor, G. J.M. Parker, and G. C. Jayson
Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Clin. Cancer Res., June 15, 2007; 13(12): 3449 - 3459.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
B. Schaffhauser, T. Veikkola, K. Strittmatter, H. Antoniadis, K. Alitalo, and G. Christofori
Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice
J. Leukoc. Biol., October 1, 2006; 80(4): 669 - 676.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Basche, D. L. Gustafson, S. N. Holden, C. L. O'Bryant, L. Gore, S. Witta, M. K. Schultz, M. Morrow, A. Levin, B. R. Creese, et al.
A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors.
Clin. Cancer Res., September 15, 2006; 12(18): 5471 - 5480.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke, E. K. Bergsland, D. P. Ryan, P. C. Enzinger, T. J. Lynch, A. X. Zhu, J. A. Meyerhardt, J. V. Heymach, W. E. Fogler, C. Sidor, et al.
Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors
J. Clin. Oncol., August 1, 2006; 24(22): 3555 - 3561.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X.-P. Li, C. Y.S. Li, X. Li, Y. Ding, L. L.Y. Chan, P.-H. Yang, G. Li, X. Liu, J. S. Lin, J. Wang, et al.
Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin
Mol. Cancer Ther., May 1, 2006; 5(5): 1290 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. H. G. Hansma, H. J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H. M. Pinedo, and K. Hoekman
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer
Ann. Onc., October 1, 2005; 16(10): 1695 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Hoekstra, F. Y.F.L. de Vos, F. A.L.M. Eskens, J. A. Gietema, A. van der Gaast, H. J.M. Groen, R. A. Knight, R. A. Carr, R. A. Humerickhouse, J. Verweij, et al.
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 5188 - 5197.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H.-M. Cho, J. D. Rosenblatt, Y.-S. Kang, M. L. Iruela-Arispe, S. L. Morrison, M. L. Penichet, Y.-G. Kwon, T.-W. Kim, K. A. Webster, H. Nechustan, et al.
Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
Mol. Cancer Ther., June 1, 2005; 4(6): 956 - 967.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Kirsch, P. Weigel, T. Pinzer, R. S. Carroll, P. McL. Black, H.-K. Schackert, and G. Schackert
Therapy of Hematogenous Melanoma Brain Metastases with Endostatin
Clin. Cancer Res., February 1, 2005; 11(3): 1259 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Studeny, F. C. Marini, J. L. Dembinski, C. Zompetta, M. Cabreira-Hansen, B. N. Bekele, R. E. Champlin, and M. Andreeff
Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents
J Natl Cancer Inst, November 3, 2004; 96(21): 1593 - 1603.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. S. Yoon, N. H. Segal, A. B. Olshen, M. F. Brennan, and S. Singer
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
Ann. Onc., August 1, 2004; 15(8): 1261 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. L. Korn
Nontoxicity Endpoints in Phase I Trial Designs for Targeted, Non-Cytotoxic Agents
J Natl Cancer Inst, July 7, 2004; 96(13): 977 - 978.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. R. Parulekar and E. A. Eisenhauer
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Yu, K. S. Moulton, M. K. Khan, S. Vineberg, E. Boye, V. M. Davis, P. E. O'Donnell, J. Bischoff, and D. S. Milstone
E-selectin is required for the antiangiogenic activity of endostatin
PNAS, May 25, 2004; 101(21): 8005 - 8010.
[Abstract] [Full Text] [PDF]

Home page
 Recent Prog Horm ResHome page
M. L. Wahl, T. L. Moser, and S. V. Pizzo
Angiostatin and Anti-angiogenic Therapy in Human Disease
Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
D. W. Davis, Y. Shen, N. A. Mullani, S. Wen, R. S. Herbst, M. O'Reilly, J. L. Abbruzzese, and D. J. McConkey
Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors
Clin. Cancer Res., January 1, 2004; 10(1): 33 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Abdollahi, K. E. Lipson, A. Sckell, H. Zieher, F. Klenke, D. Poerschke, A. Roth, X. Han, M. Krix, M. Bischof, et al.
Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects
Cancer Res., December 15, 2003; 63(24): 8890 - 8898.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Schuch, J. V. Heymach, M. Nomi, M. Machluf, J. Force, A. Atala, J. P. Eder Jr., J. Folkman, and S. Soker
Endostatin Inhibits the Vascular Endothelial Growth Factor-Induced Mobilization of Endothelial Progenitor Cells
Cancer Res., December 1, 2003; 63(23): 8345 - 8350.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. E. Daly, A. Makris, M. Reed, and C. E. Lewis
Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment?
J Natl Cancer Inst, November 19, 2003; 95(22): 1660 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q.-T. Le and A. J. Giaccia
Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer
Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Plum, A. D. Hanson, K. M. Volker, H. A. Vu, B. K. L. Sim, W. E. Fogler, and A. H. Fortier
Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model
Clin. Cancer Res., October 1, 2003; 9(12): 4619 - 4626.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. M. Weinreich, D. M. Elaraj, M. Puhlmann, S. M. Hewitt, N. M. Carroll, E. D. Feldman, E. M. Turner, P. J. Spiess, and H. R. Alexander
Effect of Interleukin 1 Receptor Antagonist Gene Transduction on Human Melanoma Xenografts in Nude Mice
Cancer Res., September 15, 2003; 63(18): 5957 - 5961.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Collins
Functional Imaging in Phase I Studies: Decorations or Decision Making?
J. Clin. Oncol., August 1, 2003; 21(15): 2807 - 2809.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. D. Hood and D. A. Cheresh
Building a better Trap
PNAS, July 22, 2003; 100(15): 8624 - 8625.
[Full Text] [PDF]

Home page
 JCOHome page
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. H. M. Schellens and M. J. Ratain
Endostatin: Are the 2 Years Up Yet?
J. Clin. Oncol., September 15, 2002; 20(18): 3758 - 3760.
[Full Text] [PDF]

Home page
 JCOHome page
C. K. Daugherty
The "Cure" for Cancer: Can the Media Report the Hope Without the Hype?
J. Clin. Oncol., September 15, 2002; 20(18): 3761 - 3764.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online